"The FDA monitors the safety of drugs throughout their life cycle, including post-approval. In addition, the FDA maintains a system of postmarketing surveillance and risk assessment programs to identify and evaluate adverse events that did not appear during the drug development process," FDA spokesperson Chanapa Tantibanchachai said in an email.
"If newly identified safety signals are identified, the FDA will determine what, if any, actions are appropriate after a thorough review of available data," Tantibanchachai added.
[
add
]
[
|
|
...
]